Other equities analysts have also issued reports about the company. ValuEngine raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, November 28th. BidaskClub downgraded shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. Zacks Investment Research downgraded shares of Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. SunTrust Banks assumed coverage on shares of Fate Therapeutics in a report on Tuesday, November 12th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Piper Jaffray Companies reduced their price target on shares of Fate Therapeutics from $30.00 to $28.00 and set an “overweight” rating on the stock in a research report on Monday, September 16th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $24.47.
Shares of Fate Therapeutics stock opened at $13.67 on Monday. Fate Therapeutics has a twelve month low of $11.00 and a twelve month high of $22.82. The stock has a market capitalization of $1.03 billion, a P/E ratio of -11.49 and a beta of 1.86. The company has a current ratio of 7.53, a quick ratio of 7.53 and a debt-to-equity ratio of 0.10. The business’s fifty day moving average price is $14.68 and its 200 day moving average price is $17.61.
In other news, insider Bahram Valamehr sold 6,200 shares of the business’s stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $14.18, for a total transaction of $87,916.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Redmile Group, Llc bought 857,143 shares of the firm’s stock in a transaction dated Monday, September 16th. The stock was purchased at an average price of $17.50 per share, with a total value of $15,000,002.50. The disclosure for this purchase can be found here. Insiders sold 37,417 shares of company stock valued at $536,649 in the last ninety days. 23.19% of the stock is owned by corporate insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Redmile Group LLC boosted its holdings in shares of Fate Therapeutics by 8.3% in the 3rd quarter. Redmile Group LLC now owns 11,216,809 shares of the biopharmaceutical company’s stock valued at $174,197,000 after buying an additional 857,143 shares during the period. Millennium Management LLC increased its holdings in shares of Fate Therapeutics by 1,812.8% in the 3rd quarter. Millennium Management LLC now owns 3,355,119 shares of the biopharmaceutical company’s stock valued at $52,105,000 after purchasing an additional 3,179,714 shares during the period. Victory Capital Management Inc. increased its position in Fate Therapeutics by 48.3% in the 2nd quarter. Victory Capital Management Inc. now owns 2,927,930 shares of the biopharmaceutical company’s stock worth $59,437,000 after purchasing an additional 953,756 shares during the last quarter. State Street Corp increased its position in Fate Therapeutics by 11.6% during the third quarter. State Street Corp now owns 2,710,736 shares of the biopharmaceutical company’s stock worth $42,098,000 after buying an additional 282,710 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in Fate Therapeutics by 98.8% in the 3rd quarter. Point72 Asset Management L.P. now owns 1,180,089 shares of the biopharmaceutical company’s stock worth $18,327,000 after buying an additional 586,589 shares during the period. 97.60% of the stock is currently owned by hedge funds and other institutional investors.
About Fate Therapeutics
Fate Therapeutics, Inc operates as a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorder. The firm programme cellular therapeutics for the treatment of life threatening diseases, hematologic malignancies, genetic disorders and diseases resulting from the dysregulation of the immune system.
See Also: How is the LIBOR rate calculated?
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.